|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 3 (February 1), 2000:
pp. 783-789
Prognosis of follicular lymphoma: a predictive model based on a
retrospective analysis of 987 cases
Massimo Federico,
Umberto Vitolo,
Pier Luigi Zinzani,
Teodoro Chisesi,
Vera Clò,
Giampiero Bellesi,
Massimo Magagnoli,
Marina Liberati,
Carola Boccomini,
Pasquale Niscola,
Vincenzo Pavone,
Antonio Cuneo,
Gino Santini,
Maura Brugiatelli,
Luca Baldini,
Luigi Rigacci, and
Luigi Resegotti for the
Intergruppo Italiano Linfomi
From the Oncologia Medica, Università di Modena, Modena,
Italia; U.O.A. Ematologia, Azienda Ospedaliera San Giovanni Battista,
Torino, Italia; Istituto di Ematologia e Oncologia Medica
Seràgnoli, Università di Bologna, Bologna, Italia;
Divisione di Ematologia, Ospedale Civile Venezia-Mestre;
Cattedra e Divisione di Ematologia, Università di Firenze,
Firenze, Italia; Clinica Medica Generale, Policlinico Monteluce,
Perugia, Italia; Dipartimento di Biotecnologie Cellulari ed
Ematologia, Università La Sapienza, Roma, Italia; Cattedra e
Servizio di Ematologia, Azienda Ospedaliera Policlinico, Bari;
Dipartimento di Scienze Biomediche, Sezione di Ematologia,
Università di Ferrara; Divisione di Ematologia
Ia , Ospedale San Martino, Genova, Italia; and
Dipartimento di Emato-Oncologia, Azienda Ospedaliera
Bianchi-Melacrino-Morelli, Reggio Calabria; Cattedra di Ematologia,
Università di Milano, Ospedale Maggiore, IRCCS, Milano, Italia. A
complete list of the members of the Intergruppo Italiano Linfomi is
given at the end of this article.
Patients (n-987) with a histologically confirmed diagnosis of
follicular lymphoma were studied with the aim of developing a
prognostic model specifically devised for this type of lymphoma. We
collected information on age, sex, Ann Arbor stage, number of
extranodal disease sites, bone marrow (BM) involvement, bulky disease,
B symptom criteria (fever, night sweats, and weight loss), performance
status (PS), serum lactate dehydrogenase (LDH) level, serum albumin
level, hemoglobin level, and erythrocyte sedimentation rate (ESR). In
the training sample of 429 patients with complete data, multivariate
analysis showed that age, sex, number of extranodal sites, B symptoms,
serum LDH level, and ESR were factors predictive for overall survival.
Using these 6 variables, a prognostic model was devised to identify 3 groups at different risk. The 5- and 10-year survival rate was 90% and
65% for patients at low risk, respectively; 75% and 54% for patients
at intermediate risk; and 38% and 11% for those at high risk
(log-rank test, 86.62; P < .0001). The model was also
predictive (P = .0001) in the validation sample of 265 patients with complete data only for the 6 variables used in the
development of the model and even in the group of 210 patients from the
validation sample uniformly treated with doxorubicin-containing
regimens (P = .0001). The prognostic model appears to be
very useful in identifying patients with follicular lymphoma at low,
intermediate, or high risk.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. A. M. van de Schans, E. W. Steyerberg, M. R. Nijziel, G.-J. Creemers, M. L. Janssen-Heijnen, and D. J. van Spronsen
Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting
Ann. Onc.,
October 1, 2009;
20(10):
1697 - 1702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, M. Bellei, L. Marcheselli, S. Luminari, A. Lopez-Guillermo, U. Vitolo, B. Pro, S. Pileri, A. Pulsoni, P. Soubeyran, et al.
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
J. Clin. Oncol.,
September 20, 2009;
27(27):
4555 - 4562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Foster, D. A. Gabriel, and T. Shea
Role of Hematopoietic Stem Cell Transplant in the Management of Follicular Lymphoma
Oncologist,
July 1, 2009;
14(7):
726 - 738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Z. Ai, R. Tibshirani, B. Taidi, D. Czerwinski, and R. Levy
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
Blood,
June 4, 2009;
113(23):
5743 - 5746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin,
September 1, 2008;
58(5):
305 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ladetto, F. De Marco, F. Benedetti, U. Vitolo, C. Patti, A. Rambaldi, A. Pulsoni, M. Musso, A. M. Liberati, A. Olivieri, et al.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Blood,
April 15, 2008;
111(8):
4004 - 4013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y Sato, K Ichimura, T Tanaka, K Takata, T Morito, H Sato, E Kondo, H Yanai, N Ohara, T Oka, et al.
Duodenal follicular lymphomas share common characteristics with mucosa-associated lymphoid tissue lymphomas
J. Clin. Pathol.,
March 1, 2008;
61(3):
377 - 381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, C. Guglielmi, S. Luminari, C. Mammi, L. Marcheselli, U. Gianelli, A. Maiorana, F. Merli, M. Bellei, S. Pozzi, et al.
Prognostic relevance of serum {beta}2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study
Haematologica,
November 1, 2007;
92(11):
1482 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Gine, S Montoto, F Bosch, L Arenillas, S Mercadal, N Villamor, A Martinez, L Colomo, E Campo, E Montserrat, et al.
The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma
Ann. Onc.,
October 1, 2006;
17(10):
1539 - 1545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Farinha, H. Masoudi, B. F. Skinnider, K. Shumansky, J. J. Spinelli, K. Gill, R. Klasa, N. Voss, J. M. Connors, and R. D. Gascoyne
Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
Blood,
September 15, 2005;
106(6):
2169 - 2174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Perea, A. Altes, S. Montoto, A. Lopez-Guillermo, E. Domingo-Domenech, A. Fernandez-Sevilla, J. M. Ribera, J. Grau, C. Pedro, J. Angel Hernandez, et al.
Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems
Ann. Onc.,
September 1, 2005;
16(9):
1508 - 1513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Glas, M. J. Kersten, L. J. M. J. Delahaye, A. T. Witteveen, R. E. Kibbelaar, A. Velds, L. F. A. Wessels, P. Joosten, R. M. Kerkhoven, R. Bernards, et al.
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment
Blood,
January 1, 2005;
105(1):
301 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Dave, G. Wright, B. Tan, A. Rosenwald, R. D. Gascoyne, W. C. Chan, R. I. Fisher, R. M. Braziel, L. M. Rimsza, T. M. Grogan, et al.
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
N. Engl. J. Med.,
November 18, 2004;
351(21):
2159 - 2169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt
rHuEPO and Treatment Outcomes: the Clinical Experience
Oncologist,
November 1, 2004;
9(suppl_5):
55 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Montoto, A. Lopez-Guillermo, A. Altes, G. Perea, A. Ferrer, M. Camos, L. Villela, F. Bosch, J. Esteve, F. Cervantes, et al.
Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression
Ann. Onc.,
October 1, 2004;
15(10):
1484 - 1489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Solal-Celigny, P. Roy, P. Colombat, J. White, J. O. Armitage, R. Arranz-Saez, W. Y. Au, M. Bellei, P. Brice, D. Caballero, et al.
Follicular Lymphoma International Prognostic Index
Blood,
September 1, 2004;
104(5):
1258 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi, S. A. Pileri, and P. L. Zinzani
Challenging paradigms in lymphoma treatment
Ann. Onc.,
May 1, 2004;
15(5):
703 - 711.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Leitch, R. D. Gascoyne, M. Chhanabhai, N. J. Voss, R. Klasa, and J. M. Connors
Limited-stage mantle-cell lymphoma
Ann. Onc.,
October 1, 2003;
14(10):
1555 - 1561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Seymour, B. Pro, L. M. Fuller, J. T. Manning, F. B. Hagemeister, J. Romaguera, M. A. Rodriguez, C. S. Ha, T. L. Smith, A. Ayala, et al.
Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I-II Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
June 1, 2003;
21(11):
2115 - 2122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Baldini, M. Brugiatelli, S. Luminari, M. Lombardo, F. Merli, S. Sacchi, P. Gobbi, M. Liberati, L. Cavanna, M. Colombi, et al.
Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi
J. Clin. Oncol.,
April 15, 2003;
21(8):
1459 - 1465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Viardot, P. Moller, J. Hogel, K. Werner, G. Mechtersheimer, A. D. Ho, G. Ott, T. F.E. Barth, R. Siebert, S. Gesk, et al.
Clinicopathologic Correlations of Genomic Gains and Losses in Follicular Lymphoma
J. Clin. Oncol.,
December 1, 2002;
20(23):
4523 - 4530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ladetto, P. Corradini, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, M. Brugiatelli, P. Coser, A. Perrotti, I. Majolino, et al.
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Blood,
August 13, 2002;
100(5):
1559 - 1565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Maartense, S. le Cessie, H. C. Kluin-Nelemans, P. M. Kluin, S. Snijder, P. W. Wijermans, and E. M. Noordijk
Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry
Ann. Onc.,
August 1, 2002;
13(8):
1275 - 1284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Montoto, A. Lopez-Guillermo, A. Ferrer, M. Camos, A. Alvarez-Larran, F. Bosch, J. Blade, F. Cervantes, J. Esteve, F. Cobo, et al.
Survival after progression in patients with follicular lymphoma: analysis of prognostic factors
Ann. Onc.,
April 1, 2002;
13(4):
523 - 530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rambaldi, M. Lazzari, C. Manzoni, E. Carlotti, L. Arcaini, M. Baccarani, T. Barbui, C. Bernasconi, G. Dastoli, G. Fuga, et al.
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
Blood,
February 1, 2002;
99(3):
856 - 862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. van Kemenade, F. M. Raaphorst, T. Blokzijl, E. Fieret, K. M. Hamer, D. P. E. Satijn, A. P. Otte, and C. J. L. M. Meijer
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma
Blood,
June 15, 2001;
97(12):
3896 - 3901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
